New hope for tough pancreatic cancer: targeted drug plus chemo shows promise
NCT ID NCT06396091
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 21 times
Summary
This early-stage study tests a new drug, zolbetuximab, combined with standard chemotherapy in people with advanced pancreatic cancer that has spread. The drug targets a protein on cancer cells to help the immune system attack them. The main goals are to check safety and find the right dose in 12 adults who haven't had chemo before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.